The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
COMy 2019 | Treatment options for relapsed myeloma: assessing the need for auto-SCT
Inger Nijhof, MD, PhD, of VU University Medical Center, Amsterdam, Netherlands, talks through the different treatment options that could be offered to relapsed multiple myeloma patients. Dr Nijhof also discusses the need to tailor the treatment depending on the patient’s risk level, for example autologous stem cell transplants may not be beneficial for low risk patients. This interview took place at the Controversies in Multiple Myeloma (COMy) 2019 World Congress in Paris, France.
